Table 1. In vitro minimum inhibitory concentration (MIC) of PAAG, oxacillin and mupirocin against S. aureus and clinical MRSA isolates.
| S. aureus Strains | MIC (μg/mL) | ||
|---|---|---|---|
| PAAG | Oxacillin | Mupirocin | |
| ATCC 6538* | 32 | <0.125 (S) | <0.125 (S) |
| MW-2 | 32 | 16 (R) | <0.125 (S) |
| SA01 | 32 | 16 (R) | <0.125 (S) |
| SA02 | 32 | 32 (R) | 16 (LR) |
| SA03 | 16 | 16 (R) | <0.125 (S) |
| SA04 | 32 | 8 (R) | <0.125 (S) |
| SA05 | 32 | 4 (R) | >64 (R) |
| SA06 | 32 | 8 (R) | 16 (LR) |
| SA07 | 32 | 16 (R) | <0.125 (S) |
| SA08 | 32 | 128 (R) | 8 (LR) |
| SA09 | 32 | 16 (R) | <0.125 (S) |
| SA10 | 32 | 64 (R) | <0.125 (S) |
| SA11 | 32 | 16 (R) | <0.125 (S) |
| SA12 | 16 | 64 (R) | <0.125 (S) |
| 2-1A | 128 | 256 (R) | >512 (HR) |
| 2-4C | 64 | 64 (R) | >512 (HR) |
| 2-5A | 64 | 128 (R) | >512 (HR) |
| 2-9A | 64 | 128 (R) | >512 (HR) |
Clinical resistance breakpoints according to CLSI: mupirocin > 512 μg/mL (high resistance -HR); 8–64 μg/mL (low resistance-LR); oxacillin ≥ 4 μg/mL (resistant–R); oxacillin < 4μg/mL (sensitive-S).
*MIC bacitracin was found to be 200 μg/mL.